381-97-5Relevant articles and documents
Lipase mediated preparation of the enantiomers of 3,3,3-trifluoro-2- methylpropanoic acid
Beier, Petr,Z. Slawin, Alexandra M.,O'Hagan, David
, p. 2447 - 2449 (2004)
Both enantiomers of 3,3,3-trifluoro-2-methylpropanoic acid were prepared by a lipase mediated kinetic resolution of the racemate. The preparation of both enantiomers of 3,3,3-trifluoro-2-methylpropanoic acid by a lipase mediated kinetic resolution of the
Low-Flammable Parahydrogen-Polarized MRI Contrast Agents
Ariyasingha, Nuwandi M.,Chekmenev, Eduard Y.,Chukanov, Nikita V.,Gelovani, Juri G.,Joalland, Baptiste,Koptyug, Igor V.,Kovtunov, Kirill V.,Nantogma, Shiraz,Salnikov, Oleg G.,Younes, Hassan R.
, p. 2774 - 2781 (2021/01/18)
Many MRI contrast agents formed with the parahydrogen-induced polarization (PHIP) technique exhibit biocompatible profiles. In the context of respiratory imaging with inhalable molecular contrast agents, the development of nonflammable contrast agents would nonetheless be highly beneficial for the biomedical translation of this sensitive, high-throughput and affordable hyperpolarization technique. To this end, we assess the hydrogenation kinetics, the polarization levels and the lifetimes of PHIP hyperpolarized products (acids, ethers and esters) at various degrees of fluorine substitution. The results highlight important trends as a function of molecular structure that are instrumental for the design of new, safe contrast agents for in vivo imaging applications of the PHIP technique, with an emphasis on the highly volatile group of ethers used as inhalable anesthetics.
PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORgT
-
Paragraph 0455, (2020/01/09)
The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.